Ozempic vs Trulicity: Head-to-Head Efficacy Compared

How SUSTAIN-7 Settled the Head-to-Head Debate

The SUSTAIN-7 trial remains the only randomized, open-label study that directly pitted semaglutide against dulaglutide in adults with type 2 diabetes. Published in 2018, this 40-week trial enrolled 1,201 patients already on metformin and randomized them to one of four arms: semaglutide 0.5 mg, semaglutide 1.0 mg, dulaglutide 0.75 mg, or dulaglutide 1.5 mg 1.

Semaglutide won on both primary endpoints. At the lower dose pairing, semaglutide 0.5 mg reduced HbA1c by 1.5% compared with 1.1% for dulaglutide 0.75 mg (estimated treatment difference: -0.40 percentage points; 95% CI -0.55 to -0.25; P<0.0001). At the higher dose pairing, semaglutide 1.0 mg achieved a 1.8% HbA1c reduction versus 1.4% for dulaglutide 1.5 mg (estimated treatment difference: -0.41 percentage points; P<0.0001) 1.

That 0.4 percentage point gap is clinically meaningful. The American Diabetes Association notes that each 1% reduction in HbA1c is associated with a 37% decrease in microvascular complications and a 21% reduction in diabetes-related death, per the UKPDS legacy analysis 2. Extrapolated over years, the incremental benefit of semaglutide's deeper glycemic control adds up.

Completion rates were similar across groups (approximately 86-90%), and the trial population had a mean baseline HbA1c of 8.2%, representative of the typical patient starting injectable GLP-1 therapy 1.

Weight Loss: Where the Gap Widens

Body weight reduction separates these two drugs more dramatically than glycemic control does. In SUSTAIN-7, semaglutide 0.5 mg produced mean weight loss of 4.6 kg versus 2.3 kg with dulaglutide 0.75 mg. The higher doses widened the margin further: semaglutide 1.0 mg led to 6.5 kg of weight loss compared with 3.0 kg for dulaglutide 1.5 mg (estimated treatment difference: -3.55 kg; P<0.0001) 1.

That means patients on semaglutide 1.0 mg lost roughly twice the weight of those on dulaglutide 1.5 mg. For a 100 kg patient, semaglutide delivered approximately 6.5% body weight reduction versus 3.0% with dulaglutide at their respective top approved diabetes doses in the trial.

Novo Nordisk later introduced the 2.0 mg dose of Ozempic, which pushed weight loss even further. In the SUSTAIN FORTE trial (N=961), semaglutide 2.0 mg produced an additional 0.18% HbA1c reduction and 1.1 kg more weight loss compared with the 1.0 mg dose at 40 weeks 3. Eli Lilly similarly expanded Trulicity's dosing with 3.0 mg and 4.5 mg options, though no head-to-head data exist comparing these higher doses against each other.

The clinical implication is straightforward. For patients whose primary treatment goal includes weight management alongside glycemic control, semaglutide offers a measurably larger effect at comparable dose tiers. For patients whose weight is less of a concern and who tolerate dulaglutide well, the switch may not be necessary.

Cardiovascular Outcomes: Different Trials, Different Populations

Both drugs have demonstrated cardiovascular safety, but their outcome trial designs differed substantially.

The REWIND trial (N=9,901) studied dulaglutide 1.5 mg over a median follow-up of 5.4 years in patients with type 2 diabetes who had either established cardiovascular disease or cardiovascular risk factors. The primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (3-point MACE) occurred in 12.0% of the dulaglutide group versus 13.4% of the placebo group (HR 0.88; 95% CI 0.79 to 0.99; P=0.026) 4.

That 12% relative risk reduction is notable for two reasons. REWIND enrolled a broader population than most cardiovascular outcome trials for diabetes drugs. Only 31% of participants had established cardiovascular disease at baseline, meaning the benefit extended to a primary prevention cohort 4. The trial also ran longer than SUSTAIN-6, providing more durable outcome data.

SUSTAIN-6 (N=3,297) evaluated semaglutide 0.5 mg and 1.0 mg over 104 weeks. The primary outcome of 3-point MACE occurred in 6.6% of semaglutide patients versus 8.9% of placebo patients (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for noninferiority) 5. The 26% relative risk reduction was numerically impressive, but the trial was powered for noninferiority rather than superiority, and the confidence intervals overlapped with REWIND's effect estimate.

Dr. Hertzel Gerstein, principal investigator of REWIND, stated: "REWIND demonstrated that dulaglutide reduces cardiovascular events in a broad population of people with type 2 diabetes, including those without prior cardiovascular disease" 4.

Direct comparison of cardiovascular outcomes between these two drugs is not possible from these trials. The populations, follow-up durations, and statistical designs differed too much to draw reliable conclusions about which drug is superior for cardiovascular protection.

Dosing and Titration Schedules

Ozempic starts at 0.25 mg weekly for four weeks (a titration dose not intended for glycemic control), then increases to 0.5 mg. If additional efficacy is needed after at least four weeks at 0.5 mg, clinicians can increase to 1.0 mg, and subsequently to the maximum 2.0 mg dose 6.

Trulicity begins at 0.75 mg weekly. After at least four weeks, the dose can move to 1.5 mg, then to 3.0 mg, and finally to the 4.5 mg maximum. Unlike Ozempic, Trulicity does not require a sub-therapeutic titration step. The starting 0.75 mg dose is a treatment dose 7.

This distinction matters in practice. Patients starting Ozempic spend the first four weeks on a dose that provides minimal glycemic benefit, while Trulicity patients begin receiving therapeutic effect from week one. For patients transitioning from oral therapy who need prompt HbA1c improvement, this timeline difference can influence prescribing decisions.

Both drugs are administered once weekly on the same day each week, with flexibility to change the injection day as long as the last dose was given at least two days (48 hours) prior. The injection can be given at any time of day, independent of meals 6 7.

Gastrointestinal Side Effects Compared

Nausea, vomiting, and diarrhea are the most common adverse events for both medications, consistent with the GLP-1 receptor agonist class.

In SUSTAIN-7, nausea occurred in 21.2% of patients on semaglutide 1.0 mg versus 17.0% on dulaglutide 1.5 mg. Diarrhea rates were 13.3% for semaglutide 1.0 mg and 11.5% for dulaglutide 1.5 mg. Vomiting was reported by 8.3% on semaglutide 1.0 mg compared with 6.0% on dulaglutide 1.5 mg 1.

These differences are modest. The discontinuation rate due to adverse events was 8% for semaglutide 1.0 mg and 6% for dulaglutide 1.5 mg, not statistically significant in the overall safety analysis 1.

Most GI symptoms peak during dose escalation and diminish within four to eight weeks at a stable dose. The American Association of Clinical Endocrinology recommends slow titration and dietary modification (smaller, lower-fat meals) to manage early GI symptoms, rather than premature discontinuation 8.

Injection site reactions follow an opposite pattern. The Trulicity pen uses a pre-attached, hidden needle that fires automatically when pressed against the skin. Ozempic requires the patient to manually attach a disposable needle to the pen before each injection. In pooled analysis from the SUSTAIN program, injection-site reactions occurred in about 0.2% of semaglutide patients 5. Dulaglutide injection-site reactions occurred in approximately 0.5-1.0% in REWIND 4.

Who Should Choose Which Drug

The 2023 ADA Standards of Care recommend GLP-1 receptor agonists as preferred injectable therapy for most patients with type 2 diabetes, particularly those with established atherosclerotic cardiovascular disease, high cardiovascular risk, or a need for weight management 9.

Semaglutide (Ozempic) is the stronger option when the clinical priority is maximal HbA1c lowering, significant weight reduction, or both. The SUSTAIN-7 data consistently showed semaglutide outperforming dulaglutide across matched dose tiers on both endpoints 1.

Dulaglutide (Trulicity) may be preferred in certain scenarios. Patients who value the simplest possible injection experience benefit from Trulicity's ready-to-use, hidden-needle pen. Patients with established cardiovascular risk factors but without prior cardiovascular events can be reassured by REWIND's primary-prevention data, the most strong in the GLP-1 class at time of publication 4.

Cost often drives the decision. Both drugs carry list prices above $900 per month without insurance. Formulary placement varies by insurer and plan year. Some commercial plans and Medicare Part D formularies preferentially cover one over the other, making the out-of-pocket difference more decisive than the clinical difference for many patients 10.

Dr. John Buse, Director of the University of North Carolina Diabetes Center, has noted: "When choosing between GLP-1 receptor agonists, the best drug is the one the patient can access, afford, and tolerate consistently" 9.

Switching Between Ozempic and Trulicity

Switching from one GLP-1 receptor agonist to another is straightforward. The general protocol is to start the new drug at its standard starting dose on the day the next injection of the previous drug was due. No washout period is required 8.

For a patient switching from Trulicity 1.5 mg to Ozempic, most clinicians start semaglutide at 0.5 mg (skipping the 0.25 mg titration step, since the patient is already GLP-1 adapted) and titrate based on response. The reverse switch, from Ozempic to Trulicity, typically starts at dulaglutide 1.5 mg for patients previously on semaglutide 0.5 mg or 1.0 mg.

Common reasons for switching include inadequate glycemic response at maximum dose, intolerable GI side effects (which sometimes resolve with a different molecule in the same class), insurance formulary changes, or supply disruptions. The GLP-1 receptor agonist shortage of 2023-2024 pushed many patients to switch between agents out of necessity rather than clinical preference 10.

Patients should expect a brief re-adjustment period of one to two weeks after switching, during which mild GI symptoms may recur. This is not a reason to abandon the new drug. Blood glucose monitoring should be intensified for the first four weeks after any GLP-1 switch, particularly for patients on concurrent sulfonylurea or insulin therapy where hypoglycemia risk may temporarily shift.

What About Newer Doses and Future Competition

Since the SUSTAIN-7 publication, both drugs have expanded their dose ranges. Ozempic added the 2.0 mg dose in 2022 based on SUSTAIN FORTE data 3. Trulicity added 3.0 mg and 4.5 mg based on the AWARD-11 trial (N=1,842), which showed HbA1c reductions of 1.5% and 1.6% at 36 weeks for the 3.0 mg and 4.5 mg doses, respectively, compared with 1.3% for 1.5 mg 11.

No head-to-head trial compares semaglutide 2.0 mg against dulaglutide 4.5 mg. Until such data exist, cross-trial comparison suggests semaglutide maintains its advantage at maximum doses, but that interpretation carries the standard limitations of indirect comparison.

The GLP-1 space continues to evolve rapidly. Tirzepatide (Mounjaro), a dual GIP/GLP-1 agonist, demonstrated superiority over semaglutide 1.0 mg in the SURPASS-2 trial (N=1,879), with HbA1c reductions of 2.0-2.3% and weight loss of 7.6-11.2 kg across tirzepatide dose tiers at 40 weeks 12. Patients currently on either Ozempic or Trulicity may be candidates for tirzepatide if they need greater efficacy than their current regimen provides.

Semaglutide 2.4 mg (marketed as Wegovy for chronic weight management) produced 14.9% mean body weight loss at 68 weeks in the STEP-1 trial (N=1,961) versus 2.4% with placebo 13. This is a different indication and dose than Ozempic, but it illustrates the broader weight-loss ceiling of the semaglutide molecule when dosed for obesity rather than diabetes.